Tag: EPZM

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Epizyme (EPZM – Research Report), with a price target of $10.00. The company’s shares closed last Wednesday at $0.47, close to its 52-week low of $0.46.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.6% and a 20.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

Epizyme has an analyst consensus of Moderate Buy, with a price target consensus of $8.50, implying a 1365.5% upside from current levels. In a report issued on May 10, Wedbush also maintained a Buy rating on the stock with a $7.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Epizyme’s market cap is currently $77.07M and has a P/E ratio of -0.19.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Read More on EPZM:

• Sinclair Broadcast (SBGI) Gets a Hold Rating from Rosenblatt Securities
• Coherent (COHR) Receives a Hold from Benchmark Co.
• Amtech Systems (ASYS) Receives a Buy from Benchmark Co.
• Analysts Are Bullish on Top Healthcare Stocks: Catalyst Pharma (CPRX), Veru (VERU)
• Context Therapeutics (CNTX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Epizyme (EPZM – Research Report), with a price target of $10.00. The company’s shares closed last Tuesday at $1.59, close to its 52-week low of $1.02.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.0% and a 32.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on Epizyme is a Moderate Buy with an average price target of $4.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $9.93 and a one-year low of $1.02. Currently, Epizyme has an average volume of 2.92M.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPZM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Read More on EPZM:

• KeyCorp (KEY) Receives a Buy from Wedbush
• Analysts Offer Insights on Technology Companies: Salesforce (CRM) and Jamf Holding (JAMF)
• Analysts Are Bullish on These Healthcare Stocks: ChemoCentryx (CCXI), Taro Pharmaceutical (TARO)
• AbbVie Strengthens Neuroscience Portfolio with Syndesi Acquisition
• H.C. Wainwright Initiates a Buy Rating on Nuvectis Pharma, Inc. (NVCT)

Barclays analyst Peter Lawson maintained a Buy rating on Epizyme (EPZM – Research Report) on January 13 and set a price target of $4.00. The company’s shares closed last Friday at $2.17, close to its 52-week low of $2.16.

According to TipRanks.com, Lawson is a 3-star analyst with an average return of 4.2% and a 43.3% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Karyopharm Therapeutics, and Prelude Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $10.33 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $12.69 and a one-year low of $2.16. Currently, Epizyme has an average volume of 1.63M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Read More on EPZM:

• Coca-Cola Europacific Partners (CCEP) Receives a Buy from Barclays
• Barclays Reaffirms Their Buy Rating on Mondelez International (MDLZ)
• Barclays Maintains Their Buy Rating on Vale SA (VALE)
• Hain Celestial (HAIN) Gets a Hold Rating from Barclays
• Barclays Believes Procter & Gamble (PG) Won’t Stop Here

In a report issued on October 28, Andrew Berens from Leerink Partners maintained a Buy rating on Epizyme (EPZM – Research Report), with a price target of $16.00. The company’s shares closed last Friday at $4.50, close to its 52-week low of $4.08.

According to TipRanks.com, Berens is a 4-star analyst with an average return of 5.2% and a 58.8% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

Epizyme has an analyst consensus of Strong Buy, with a price target consensus of $13.50, implying a 186.6% upside from current levels. In a report issued on November 9, Cowen & Co. also maintained a Buy rating on the stock with a $12.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Epizyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $13.01 million and GAAP net loss of $64.36 million. In comparison, last year the company earned revenue of $2.47 million and had a GAAP net loss of $58.45 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Read More on EPZM:

• Leerink Partners Thinks Viracta Therapeutics’ Stock is Going to Recover
• AVEO Pharma (AVEO) Gets a Buy Rating from Leerink Partners
• Leerink Partners Thinks Elevation Oncology’s Stock is Going to Recover
• Cogent Biosciences (COGT) Gets a Buy Rating from Leerink Partners
• Zymeworks (ZYME) Gets a Hold Rating from Leerink Partners